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“We believe your genetic information should be controlled by you.”1 
Under that banner of individual auton-
omy, the consumer genetics firm 
23andMe conducted personalized 
genetic testing until it was stopped in 
November 2013 by the United States 
Food and Drug Administration (FDA). 
The FDA ban occasioned a fierce dispute 
between proponents of appropriate regu-
lation and defenders of the libertarian 
view that the only person deciding 
whether you should have a genetic test 
should indeed be you. This debate has 
centred on whether consumers are the 
best judges of their own clinical care. In 
this article, I also examine whether the 
science of personalized medicine is 
really as advanced as its proponents 
claim, and how the availability of genetic 
markers affects decisions on who gets 
and does not get medical treatment.
In its decision, the FDA cited con-
cerns about inaccuracy arising from 
the limited sample of markers being 
tested. Researchers have found that test 
results from different consumer genet-
ics companies for common diseases, 
such as diabetes and prostate cancer, 
can be radically inconsistent because 
of the low number of markers tested 
and the small amounts of genetic vari-
ance explained by each marker.2 In 
fact, genetic tests offered by direct-to-
consumer firms only sample a small 
proportion of single-nucleotide poly-
morphisms, (i.e., the points where the 
genomes of different individuals vary 
by a single DNA base pair).
In October 2015, 23andMe obtained 
permission from the FDA to resume a 
limited version of its genetic testing 
operations. The company previously 
covered the risk propensity for 254 
inherited diseases; however, it is now 
only allowed to provide nonmedical 
ancestry tests and carrier data for 36 
conditions, which include sickle cell 
anemia and cystic fibrosis. It is not 
permitted to perform pharmacogenetic 
analyses of an individual’s tolerance 
for a particular drug regimen, such as 
chemotherapy or warfarin.
This final limitation is important, 
because at the outset, personalized 
direct-to-consumer genetic testing was 
widely hailed as the first staging post 
in the race to develop new forms of 
medicine that would potentially allow 
physicians to offer care tailored to the 
individual’s genome rather than the 
“one-size-fits-all” model. Variously 
called precision, personalized or strati-
fied medicine, this approach was 
termed “a true revolution in medicine” 
by Francis Collins, former co-director 
of the Human Genome Project, but this 
assertion is debatable.3
Personalized medicine’s claim is 
arguably strongest in the area of pharma-
cogenetics, the relation of heritable varia-
tion to individual differences in drug 
response. Here, the goal is to minimize 
adverse drug reactions and increase effi-
cacy by tailoring the drug regimen to the 
sequenced genomes of both the patient 
and the cancer. This double approach is 
crucial because cancer is frequently het-
erogeneous (e.g., after sequencing the 
genomes of breast cancers in 50 patients, 
researchers found that only 10% of the 
tumours had more than three mutations 
in common).4
Recent studies have often confirmed 
or reconfirmed the value of the pharma-
cogenetic approach. An analysis of 
1380  gliomas, involving patients who 
were classified according to three 
genetic mutations in the tumours, found 
that the prevalent histologic approach 
was less effective than a genomic one 
for predicting response to treatment and 
overall prognosis.5 A genetic map of 
prostate cancer in 150 patients, which 
showed that it comprises several dis-
eases responsive to different treat-
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ments, also analyzed the genetic basis 
for resistance to the standard therapies 
as a result of specific DNA mutations.6
However, other recent studies have 
revealed serious clinical and ethical 
limitations of the pharmacogenetic 
approach. An analysis involving 815 
patients with cancer showed that 
sequencing tumour genomes for clues 
to genetic changes can actually misdi-
rect individualized treatment in nearly 
half of patients, unless this sequencing 
is first compared with a genetic read-
out of the patient’s noncancerous tis-
sue. Two-thirds of genetic changes iden-
tified with tumour-only sequencing were 
false-positive results, which means 
patients might be given the wrong tar-
geted treatments.7
This study undermines the standard 
argument about resource allocation and 
personalized medicine: even though 
pharmacogenetic drugs are frequently 
more expensive, this form of personal-
ized medicine is more cost-effective 
because only those patients who would 
benefit from treatment receive it. The 
ethos of pharmacogenetics is “the right 
treatment for the right patient at the 
right time.” However, such a high rate 
of false-positive results could mean the 
wrong treatment for the “right” patient.
In other cases, genetic testing might 
result in some patients being denied treat-
ment, which raises ethical issues about 
resource allocation. For example, genetic 
markers can predict the probability and 
severity of immune reaction in kidney 
transplant patients.8 Would it be ethical to 
select potential kidney recipients primar-
ily or solely on a genetic basis? Although 
individualized genetic testing does not 
create the ethical dilemma arising from 
the need to make choices — because of 
the shortage of donor kidneys — it does 
not dispel it either.
Arguably, it is more efficient and 
equitable to use advances in genetic 
sequencing to maximize the chances 
that the scarce resource of a donated 
kidney will be put to successful use. But 
we must also confront the problem of 
false-negative results, the mirror image 
of the false-positive problem raised by 
the study on prostate cancer. Suppose a 
potential recipient is wrongly identified 
as genetically more likely to reject the 
kidney and is disqualified for the trans-
plant on that basis. This problem is 
exacerbated by the probabilistic nature 
of genetic analysis, which rarely yields 
black-and-white answers. Should a 
patient get a kidney, or a drug, if there 
is only a 20% chance that he or she will 
respond favourably based on genetic pro-
file? Ten per cent? One per cent? Where 
shall we draw the line?
The ethics of resource allocation, 
that area of “tragic choices”9 in medi-
cine, offers two main alternatives for 
answering such questions. We can 
select who shall receive a scarce 
resource on the basis of prognosis: giv-
ing the kidney or drug to the patient 
with the best chance of recovery. Such 
systems of triage have long been used 
by medicine, although they are some-
times controversial. Choosing on the 
basis of the genetic likelihood of 
immune system rejection is a variant of 
this prognosis-based approach. Of 
course, in a clinical context, many other 
factors (e.g., patient age and family 
history) are also likely to be considered 
and will probably provide more accu-
rate information than personalized 
genetic screening.10
The alternative model of resource 
allocation is by diagnosis. Here, the 
argument is that justice demands we 
should give the resource to those with 
the most pressing medical need, not the 
best predicted outcome. We often 
favour this second criterion. For exam-
ple, in palliative care we think that 
dying patients should receive more 
medical resources than their terminal 
prognosis would dictate. Similarly, we 
might want to give the patient with no 
other alternative an expensive pharma-
cogenetic drug, even if his or her geneti-
cally ascertained prognosis for the drug’s 
likely success is less favourable than in 
other patients.
As a medical ethicist, I would have 
qualms about dividing patients into treat-
ment and nontreatment camps purely on 
the basis of a genetic prognosis, particu-
larly when genetic prognosis is still 
such an inexact science. A patient who 
has no other alternative may want to 
take his or her chances with a pharmaco-
genetic drug. Although personalized 
medicine is framed in the language of 
individual rights and autonomy, resource 
allocation decisions are ultimately made 
by others. Particularly in an era of aus-
terity and cost-cutting, the possibility 
that decision-makers will use genetic 
testing to limit patients’ “right to choose” 
is far from remote.
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